文献速递银屑病与炎症性皮肤病

体重≥90 kg的银屑病患者中,司库奇尤单抗每2周给药对比每4周给药疗效更优:一项随机对照试验结果

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
PubMed 文献 · Br J Dermatol · 2022-04-08

这项多中心、双盲、平行组随机对照试验纳入331例体重≥90 kg的中重度慢性斑块状银屑病患者,比较司库奇尤单抗300 mg每2周(Q2W)与每4周(Q4W)给药。第16周Q2W组PASI 90应答率显著高于Q4W组(73.2% vs 55.5%,单侧P=0.0003,OR 2.3,95%CI 1.4-3.8),第52周疗效维持且安全性相当。第16周Q4W未达PASI 90者上调至Q2W后第32周PASI 90应答率高于继续Q4W者(38.7% vs 16.5%)。

要点

  • 体重≥90 kg的中重度斑块状银屑病患者,司库奇尤单抗300 mg Q2W较Q4W显著提高第16周PASI 90应答率。
  • 第52周Q2W组PASI 75/90/100应答率均高于Q4W组,安全性相当。
  • Q4W治疗第16周未达PASI 90者上调至Q2W可获得额外获益。

核心结论

  • 在体重≥90 kg的中重度斑块状银屑病患者中,司库奇尤单抗300 mg Q2W较Q4W显示出更优且持续的疗效。
  • 第16周Q4W未达PASI 90者上调至Q2W方案可获得额外获益。

研究设计与样本

  • 多中心、双盲、平行组随机对照试验,纳入331例体重≥90 kg的中重度慢性斑块状银屑病患者。
  • 患者随机接受司库奇尤单抗300 mg Q2W或300 mg Q4W;第16周Q4W未达PASI 90者重新分配为继续Q4W或上调至Q2W。

主要发现

  • 第16周Q2W组(n=165)PASI 90应答率为73.2%,Q4W组(n=166)为55.5%,单侧P=0.0003,OR 2.3(95%CI 1.4-3.8)。
  • 第52周Q2W组(n=165)对比Q4W组(n=83):PASI 75为88.9% vs 74.8%,PASI 90为76.4% vs 52.4%,PASI 100为46.7% vs 27.3%,IGA 0/1为75.9% vs 55.6%,DLQI 0/1为66.1% vs 48.8%。
  • 第16周Q4W未达PASI 90者上调至Q2W(n=31)后第32周PASI 90应答率为38.7%,继续Q4W者(n=40)为16.5%。
  • 安全性结果在各治疗组间相当,与司库奇尤单抗已知安全性特征一致。

关键数值与推荐

  • 第16周Q2W组PASI 90应答率73.2% vs Q4W组55.5%,单侧P=0.0003,OR 2.3(95%CI 1.4-3.8)。
  • 第52周Q2W组对比Q4W组:PASI 75 88.9% vs 74.8%,PASI 90 76.4% vs 52.4%,PASI 100 46.7% vs 27.3%,IGA 0/1 75.9% vs 55.6%,DLQI 0/1 66.1% vs 48.8%。
  • 第16周Q4W未达PASI 90者上调至Q2W后第32周PASI 90应答率38.7% vs 继续Q4W者16.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a common comorbidity of psoriasis and can attenuate response to biologic treatment. OBJECTIVES: To investigate the efficacy, safety and tolerability of secukinumab 300 mg every 2 weeks (Q2W) vs. secukinumab 300 mg every 4 weeks (Q4W) in patients with a higher bodyweight. METHODS: In this multicentre, double-blind, parallel-group trial, 331 patients with moderate-to-severe chronic plaque psoriasis weighing ≥ 90 kg were randomized to receive secukinumab 300 mg Q2W or secukinumab 300 mg Q4W. Patients who did not achieve Psoriasis Area and Severity Index (PASI) 90 at week 16 on the Q4W regimen were reallocated to remain on the Q4W regimen or uptitrate to Q2W. RESULTS: At week 16, Q2W dosing (n = 165) led to significantly higher PASI 90 responses vs. Q4W [n = 166; 73.2% vs. 55.5%, one-sided P-value = 0.0003, odds ratio estimate (95% confidence intervals): 2.3 (1.4-3.8)]. At week 52, higher efficacy responses were maintained in the Q2W arm (n = 165) vs. Q4W (n = 83); PASI 75: 88.9% vs. 74.8%; PASI 90: 76.4% vs. 52.4%; PASI 100: 46.7% vs. 27.3%; Investigator's Global Assessment 0/1: 75.9% vs. 55.6% and Dermatology Life Quality Index 0/1: 66.1% vs. 48.8%. PASI 90 nonresponders at week 16 who uptitrated to Q2W (n = 31) showed higher efficacy responses at week 32 (16 weeks post-uptitration, PASI 90: 38.7% vs. 16.5%) vs. those who remained on Q4W (n = 40). Safety results were comparable across treatment arms and consistent with the established secukinumab safety profile. CONCLUSIONS: Secukinumab 300 mg Q2W demonstrated superior and sustained efficacy compared with Q4W in patients with moderate-to-severe plaque psoriasis weighing ≥ 90 kg. PASI 90 nonresponders derived additional benefits from uptitration to a Q2W regimen (ClinicalTrials.gov identifier: NCT03504852). What is already known about this topic? Obesity is a common comorbidity of psoriasis and can attenuate response to biologic treatment. Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A in the treatment of moderate-to-severe plaque psoriasis. Subgroup analyses of previous study results and pharmacokinetic/pharmacodynamic modelling data suggest that heavier patients may benefit from higher exposure to secukinumab through an increased dosing frequency [300 mg every 2 weeks (Q2W) vs. every 4 weeks (Q4W)]. What does this study add? Over 52 weeks, secukinumab 300 mg Q2W demonstrated superior efficacy compared with secukinumab 300 mg Q4W in patients with moderate-to-severe plaque psoriasis weighing ≥90 kg, with comparable safety results, consistent with the established secukinumab safety profile. In patients who did not achieve PASI 90 at week 16 on the Q4W regimen, uptitration to the Q2W regimen at week 16 resulted in improved efficacy responses through week 52 after switching.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022. PMID: 34981829. doi:10.1111/bjd.20971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。